Indian Gaucher Disease Treatment Market size stood at around USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.
Gaucher Disease is an inherited disorder resulting build-up of certain fatty substance in certain organ, mainly in liver, bone marrow and spleen. It is the most common lysosomal storage disorders. Due to the low level of glucocerebrosidase an enzyme that breaks down the fatty chemical in the body known as glucocerebroside. Gaucher cells are normal scavenger cells known as macrophages that become full of unprocessed glucocerebroside. These unprocessed gaucher cells accumulate primarily in the sleep, liver and bone marrow and causes serious orang dysfunction and inflammation. Each pregnant female has a 1 in 4 chance that the baby will be born with the disease. Moreover, several pain reregulating therapies, blood transfusions, and orthopaedic surgery are used for Gaucher disease management. ERT helps in compensating the low levels of enzyme GBA, by providing Glucocerebrosidase into the Gaucher cells. Enzyme Replacement Therapy helps in providing relief from the symptoms associated with hematologic, visceral, and bone in the Gaucher disease patients.
Market Driving Factors
The Gaucher Disease Treatment Market is majorly driven by the factors such as increasing prevalence of this disease in all age men & women and subsequent increase in the number of drugs available in the market. Also, the rising number of investments by the key players and research institute for developing new drugs that act effectively in treating type II & type III Gaucher disease. Additionally, increasing government initiatives for creating awareness about Gaucher disease will also boost the Gaucher Disease market in the coming years. Gaucher disease causes massive clinical heterogeneity with symptoms of painless splenomegaly, anemia or thrombocytopenia, bone pain, chronic fatigue and pathologic fractures and also contributes to easy incidence of bruising and bleeding through the nose. Initially, Gaucher disease was treated in patients by the use of recombinant enzyme imiglucerase which was effective in retrograding the visceral and hematologic symptoms of the disease. With advancements in research and development, the scope for medicine with enhanced treating capabilities is growing significantly. Such factors are considered to promote significantly towards the growth of the Indian Gaucher disease treatment market.